Company Filing History:

8 out of 1,215

The United States of America As Represented by the Department of Health

patents

3 out of 2,202

The United States of America As Represented by the Secretary of

Years Active: 1983-1999

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5990296 - Single chain B3 antibody fusion proteins and their uses (1999-11-23),

2. 5846535 - Methods for reducing tumor cell growth by using antibodies with broad (1998-12-08),

3. 5817313 - Monoclonal antibodies and conjugates thereof useful for the treatment of (1998-10-06),

4. 5612032 - Method for diagnosing tumors using mouse monoclonal antibodies (1997-03-18),

5. 5608039 - Single chain B3 antibody fusion proteins and their uses (1997-03-04),

6. 5525337 - Monoclonal antibody binding cell surface antigens for diagnosing cancer (1996-06-11),

7. 5320956 - Monoclonal antibody useful for the diagnosis of cancer (1994-06-14),

8. 5242813 - Mouse monoclonal antibodies specific for normal primate tissue, (1993-09-07),

9. 4958009 - Anti-human ovarian cancer immunotoxins and methods of use thereof (1990-09-18),

10. 4806494 - Monoclonal antibody against ovarian cancer cells (OVB-3) (1989-02-21),

11. 4545985 - Pseudomonas exotoxin conjugate immunotoxins (1985-10-08),

12. 4396628 - Antiviral activities of dansylcadaverine and closely related compounds (1983-08-02),

Title: Mark C Willingham: Innovator in Antibody Technology

Introduction

Mark C Willingham is a prominent inventor based in Bethesda, MD (US). He has made significant contributions to the field of antibody technology, holding a total of 12 patents. His work focuses on developing innovative solutions for medical applications, particularly in cancer treatment.

Latest Patents

One of Willingham's latest patents is for "Single chain B3 antibody fusion proteins and their uses." This invention provides recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention offers single chain Fv regions of the monoclonal antibody B3. Additionally, he has developed methods for improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region by mutating position 95 to a serine. Another significant contribution is related to methods for reducing tumor cell growth in mammals by administering compositions that include an antibody with the binding specificity of a monoclonal antibody selected from the group comprising B1, B3, or B5, conjugated to a toxin, radionuclide, or drug.

Career Highlights

Throughout his career, Willingham has worked with esteemed organizations, including the United States of America as represented by the Department of Health and the United States of America as represented by the Secretary of Health. His innovative work has positioned him as a key figure in the development of therapeutic antibodies.

Collaborations

Willingham has collaborated with notable individuals in his field, including Ira H Pastan and Kai Chang. Their combined expertise has contributed to advancements in antibody research and development.

Conclusion

Mark C Willingham's contributions to antibody technology have had a profound impact on medical science. His innovative patents and collaborations continue to pave the way for advancements in cancer treatment and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.